BIO-TECHNE Corp
TECH- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000842023
No open-market purchases or sales by BIO-TECHNE Corp insiders were filed in the last 90 days; 597 institutions reported holding it in 13F filings for Q2 2026, worth $12.3B in total; 3 superinvestors hold it, including Maverick Capital and Weitz Investment Management.
Q3 2023 vs. Q2 2023
How the institutions holding BIO-TECHNE Corp changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Of which not filed for Q3 2023 | Q3 2023 | Change |
|---|---|---|---|---|
| Holders | 529 | 3 | 530 | +4 |
| Shares | 151.2M | 331.6K | 152.2M | +1.39M (+0.9%) |
| Value | $12.3B | $27.1M | $10.4B | −$1.95B (−15.8%) |
3 institutions that held it in Q2 2023 haven't filed for Q3 2023 yet. Not filing isn't selling, so the changes leave them out.
New holders (60)
Institutions that held BIO-TECHNE Corp at the end of Q3 2023 but not at the end of Q2 2023.
Sold out (56)
Institutions that held BIO-TECHNE Corp at the end of Q2 2023 and filed for Q3 2023 without it.
Not filed for Q3 2023 yet (3)
Institutions that held BIO-TECHNE Corp at the end of Q2 2023 and haven't filed a 13F for Q3 2023. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Pictet Asset Management SA | 312,999 | $25.6M |
| Ascension Asset Management LLC | 17,552 | $1.43M |
| BerganKDV Wealth Management, LLC | 1,068 | $87.2K |